Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: ASCO Tumor Boards

This is a case-based activity that includes discussion of a 40 year old woman presenting in the clinic for a right breast mass found on self-breast examination. A bilateral mammogram showed a BIRADS-4 lesion; ultrasound and breast MRI did not reveal any additional masses or adenopathy. The patient underwent ultrasound guided core biopsy, and pathology revealed a Grade 2 infiltrating ductal carcinoma. Immunohistochemistry studies revealed a strong estrogen receptor and progesterone receptor expression and negative for HER2 overexpression. Family history reveals a mother diagnosed with breast cancer at the age of 70.

The patient elected to undergo a bilateral mastectomy with right sentinel lymph node biopsy with immediate latissimus and implant reconstruction. She did well post-operatively and was referred to a medical oncologist to discuss adjuvant therapy options.

Learning Objectives

  • Discuss the incidence and characteristics of premenopausal breast cancer patients
  • Discuss the role of ovarian suppression and aromatase inhibitors as an adjuvant therapy
  • Evaluate the optimal therapy and duration of adjuvant hormonal therapy in premenopausal women

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes

  • This course expires on July 20, 2019. Participants must complete all necessary course components by this date.
  • This course is available as part of the 2016 ASCO Tumor Boards bundle.